B7-H3 as a Prognostic Biomarker and Therapeutic Target in Pediatric central nervous system Tumors.

ABSTRACT: B7-H3 (CD276), a member of the B7 superfamily, is an important factor in downregulating immune responses against tumors. It is also aberrantly expressed in many human malignancies. Beyond immune regulatory roles, its overexpression has been linked to invasive metastatic potential and poor prognosis in patients with cancer. Antibody-dependent cell-mediated cytotoxicity strategies targeting B7-H3 are currently in development, and early-phase clinical trials have shown encouraging preliminary results. To understand the role of B7-H3 in pediatric central nervous system (CNS) malignancies, a comprehensive panel of primary CNS tumors of childhood was examined by immunohistochemistry for levels and extent of B7-H3 expression. In addition, B7-H3 m-RNA expression status and association with overall

SUBMITTER: Maachani UB 

PROVIDER: S-EPMC6938869 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature